Glucotrack, Inc. · NASDAQ:GCTK

Glucotrack — Investor Presentation (December 2025)

25 slides from Glucotrack's investor presentation, December 2025

Slide 2: Important Disclaimers
Important Disclaimers This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this presentation that are not statements of historical fact may be deemed to be forward-looking statements. Without limitin
Slide 3: Redefining the Future of Glucose Monitoring
Redefining the Future of Glucose Monitoring Our mission is to push the boundaries of diabetes management Continuous Blood Glucose Monitor (CBGM) Glucotrack’s fully implantable, long-term system is designed to be less intrusive, more accurate, and dramatically easier to live with than traditional CGM
Slide 4: Designed for the Market's Gaps. Built for the Market's Growth.
Designed for the Market’s Gaps. Built for the Market’s Growth. Differentiated product • Fully implantable CBGM system offering 3 years of continuous monitoring with no wearable • Eliminates key CGM barriers: discomfort, visibility, short sensor life, and daily maintenance • Built on proven cardiovas
Slide 5: An Experienced Team to Deliver the Next Standard of Care
An Experienced Team to Deliver the Next Standard of Care Paul V. Goode, PhD Drinda Benjamin, MBA Sandie Martha, MS Mark Tapsak, PhD President & CEO VP, Marketing VP, Clinical Operations Chief Scientific Officer • Glucose monitoring • Glucose monitoring • Glucose monitoring • Glucose monitoring • Imp
Slide 6: Innovation in Glucose Monitoring Can't Wait
Innovation in Glucose Monitoring Can’t Wait The diabetes crisis is driving healthcare resource strain 1 in 10 adults have diabetes---that’s a total of 38 million adults (and it’s the 8th-leading cause of death in the United States) 1 Diabetes is the #1 cause of >25% of US healthcare dollars blindnes
Slide 7: A Sizeable Global Diabetes Market… and CGM is Just Getting Started
A Sizeable Global Diabetes Market… and CGM is Just Getting Started Growth by Product Type (2006–2024)1 • CGM ranks among the fastest-growing categories (and is the fastest-growing device), seeing consistent year-over-year growth • GLP-1 class, with explosive growth—now the largest segment at $38.4B
Slide 8: CGM is Growing Rapidly…But ~50% of the Market Remains Untapped
Continuous Glucose Monitoring (CGM) is Growing Rapidly…But ~50% of the Market Remains Untapped CGM Global Quarterly Revenue ($ millions) 1 • $11.6B global CGM market in 20241 (approximately 50% US) – Q4 2025 revenue of $3.2B; +19%YOY; +11% sequential • Since 1999, CGM adoption has increased dramatic
Slide 9: Current CGM Penetration Across Population Cohorts
Current CGM Penetration Across Population Cohorts By Diabetes Type and Insulin Regimen Diabetes Segments by Size (M) 30.0 25.0M 25.0 20.0 15.0 10.0 3.0M 3.5M 5.0 1.8M 2.4M 0.0 Type 1 Type 2 Insulin Intensive Type 2 Basal Type 2 Hypo Risk Type 2 Non-Insulin 55% 40% 10% <5% <5% Market Penetration Some
Slide 10: CGM is a Step in the Right Direction, but Far From Optimal
CGM is a Step in the Right Direction, but Far From Optimal CGMs have become standard of care with proven clinical outcomes for improved glycemic management; however, adoption and continued adherence continues to fall below HCP expectations Attributes Shortcomings Wearable adhesives can cause discomf
Slide 11: What Patients Want (But Still Are Not Getting)
What Patients Want (But Still Are Not Getting) Unaddressed patient needs growing in importance Reference: dQ&A Q1 2018 Market Research - Base CGM users (N=1,306); dQ&A Q3 2023 Market Research - Base CGM users (N=3,426). 11 © Copyright 2025. All rights reserved. Glucotrack.
Slide 12: The Glucotrack Solution: a Breakthrough Long-Term CBGM System
The Glucotrack Solution: a Breakthrough Long-Term CBGM System • A first-of-its-kind system that combines the best of glucose monitoring and cardiac monitoring technology in one device • Designed from FDA-approved components and adopted techniques to accelerate development and reduce regulatory risk
Slide 13: Leveraging Cardiology Implant Specialists for a Cardiometabolic Condition
Leveraging Cardiology Implant Specialists for a Cardiometabolic Condition • Diabetes significantly increases the risk of HCPs Seen in Past 12 Months2 heart disease, heart failure, and stroke 80% • Cardiologists have a greater role in diabetes 70% 70% care, existing relationships and referral 60% pat
Slide 14: Putting Risk in Perspective When Considering CBGM
Putting Risk in Perspective When Considering CBGM • Implant risks are very low1 (i.e., pacemaker) • The real threat is uncontrolled diabetes2 – Proven, safe outpatient procedure, local anesthesia even when utilizing conventional CGM – Simple, fast, familiar insertion and removal steps – Severe Hypog
Slide 15: What Makes Our CBGM Different?
What Makes Our CBGM Different? Our value proposition is simple, unique and ownable Our implantable CBGM delivers 3 years of continuous, blood-true accuracy with no external wearables or daily upkeep. The results, peace of mind and the freedom to live life without compromise. Implant once, monitor fo
Slide 16: CBGM Targeted Populations
CBGM Targeted Populations Four targeted segments rely on CGM daily • Approximately 10.7M people with clinical consensus and broad coverage – 2017: CMS coverage of CGM for T1D – 2021: ADA recommends CGM use and considers it standard of care – 2023: CMS coverage of CGM for T2D using intensive insulin
Slide 17: Segmentation Illustrates Large Market Opportunity
Segmentation Illustrates Large Market Opportunity Product feature set outweighs implant procedure concerns • Addresses behavioral, demographic, and psychographic insights Population Cohorts Target Serviceable Cohort Size (Total Available Market) Segments Market Type 1 1,800,000 32% 576,600 Type 2 In
Slide 18: Successful First in Human Study Results
Successful First in Human Study Results Potential for market-leading sensor accuracy • 6 participants with type 1 diabetes or insulin using type 2 diabetes using prototype external electronics • Key Results: – All primary and secondary endpoints met – 99% data capture rate • 113 (91.62%) within – MA
Slide 19: Clinical and Regulatory Timeline
Clinical and Regulatory Timeline Leveraging proven regulatory strategies – DeNovo 510k Pathway US Pilot IDE US Pivotal US Pivotal US Pivotal 1 year approval submission begins completion FDA DeNovo 510k submission (1-year data) 2026 2027 2028 2029 US Pivotal US Pilot IDE US Pilot IDE FDA Approval enr
Slide 20: Engineered for What Patients Want (and Conventional CGMs Can't Deliver)
Engineered for What Patients Want (and Conventional CGMs Can’t Deliver) Unsurpassed longevity: Placed once every 3 years in a 20-minute outpatient procedure (vs every 15 days) Wearable-free comfort: Fully implantable design eliminates on-body devices, improving lifestyle fit Implant once. and compli
Slide 21: Poised for Impact. Positioned for Growth.
Poised for Impact. Positioned for Growth. Glucotrack is pioneering a fully implantable, long-term CBGM system engineered to overcome the limitations of traditional CGMs Unlock adoption among Benefit from strong market the ~50% of patients not tailwinds in diabetes, digital using CGM today With a pro
Slide 23: Scientific Meeting Poster Presentations
Scientific Meeting Poster Presentations Endocrinologists’ Perspectives on an Implantable Continuous Blood Glucose Monitor Kim Gerber, BBA; Richard Wood, MBA; Braxton Dalton; Drinda Benjamin, MBA; Samantha Wakil, PhD; Paul V. Goode, PhD Poster presentation at the ADCES25 Annual Conference, hosted by
Slide 24: Independent Board of Directors of Dedicated Medical Technology Veterans
Independent Board of Directors of Dedicated Medical Technology Veterans With over 30 years of leadership in the med tech industry, Mr. Malavé specializes in diabetes management across all company s tages. He excels in product Luis Malavé, development, operations, marketing, strategic partnerships, a

Glucotrack — Investor Presentation (December 2025) on 6ix

Glucotrack — Investor Presentation (December 2025)

Slide 1: Advancing Diabetes Management

Slide 2: Important Disclaimers

Slide 3: Redefining the Future of Glucose Monitoring

Slide 4: Designed for the Market's Gaps. Built for the Market's Growth.

Slide 5: An Experienced Team to Deliver the Next Standard of Care

Slide 6: Innovation in Glucose Monitoring Can't Wait

Slide 7: A Sizeable Global Diabetes Market… and CGM is Just Getting Started

Slide 8: CGM is Growing Rapidly…But ~50% of the Market Remains Untapped

Slide 9: Current CGM Penetration Across Population Cohorts

Slide 10: CGM is a Step in the Right Direction, but Far From Optimal

Slide 11: What Patients Want (But Still Are Not Getting)

Slide 12: The Glucotrack Solution: a Breakthrough Long-Term CBGM System

Slide 13: Leveraging Cardiology Implant Specialists for a Cardiometabolic Condition

Slide 14: Putting Risk in Perspective When Considering CBGM

Slide 15: What Makes Our CBGM Different?

Slide 16: CBGM Targeted Populations

Slide 17: Segmentation Illustrates Large Market Opportunity

Slide 18: Successful First in Human Study Results

Slide 19: Clinical and Regulatory Timeline

Slide 20: Engineered for What Patients Want (and Conventional CGMs Can't Deliver)

Slide 21: Poised for Impact. Positioned for Growth.

Slide 22: Appendix

Slide 23: Scientific Meeting Poster Presentations

Slide 24: Independent Board of Directors of Dedicated Medical Technology Veterans

Slide 25: Thank You